Overactive Bladder Treatment Market Analysis

Therapy (Anticholinergics, Mirabegron, Neurostimulation, Intravesical Instillation)

The neurostimulation segment is estimated to hold around 40% share of the overactive bladder treatment market in the coming years owing to the benefits offered by neurostimulation therapy. Overactive bladder (OAB) may be treated with neurostimulation, which uses a neurostimulator device to stimulate the sacral nerves. This has the potential to control bladder function and lessen the symptoms of OAB including frequent and urgent urination.

Moreover, neurostimulation is typically performed as an outpatient procedure and is comparatively non-invasive to other procedures. Additionally, compared to medicines, which could result in constipation, dry mouth, and other side effects neurostimulation has fewer systemic side effects.

Disease Type (Idiopathic Overactive Bladder, Neurogenic Overactive Bladder)

The idiopathic overactive bladder segment in the overactive bladder treatment market is set to garner a notable share of over 50% in the near future. Overactive bladder caused by idiopathic causes is more common than overactive bladder caused by neurogenic causes and the majority of OAB and detrusor overactivity instances are "idiopathic”. The symptoms describe OAB symptoms for which there is no underlying cause such as found in obesity.  Since OAB symptoms including urge incontinence, and urine urgency could be effectively decreased or eliminated with overactive bladder treatment, it is often used to treat idiopathic OAB.

Our in-depth analysis of the global market includes the following segments: